anti-Cytochrome P450, Family 4, Subfamily V, Polypeptide 2 (CYP4V2) Antibodies

CYP4V2 encodes a member of the cytochrome P450 hemethiolate protein superfamily which are involved in oxidizing various substrates in the metabolic pathway. Additionally we are shipping Cytochrome P450, Family 4, Subfamily V, Polypeptide 2 Proteins (2) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
CYP4V2 285440 Q6ZWL3
CYP4V2 510156  
CYP4V2    
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-Cytochrome P450, Family 4, Subfamily V, Polypeptide 2 Antibodies at antibodies-online.com

Showing 10 out of 47 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Delivery Price Details
Cow Rabbit Un-conjugated WB WB Suggested Anti-CYP4V2 Antibody Titration: 0.2-1 ug/mlELISA Titer: 1:312500Positive Control: Jurkat cell lysate 100 μL 2 to 3 Days
$289.00
Details
Cow Rabbit Un-conjugated WB 100 μL 11 to 14 Days
$551.83
Details
Human Rabbit Un-conjugated ELISA, ICC, IF, IHC, WB Western blot analysis of extracts from Jurkat cells, using CYP4V2 antibody. ABIN6275808 staining Hela cells by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25¡ãC. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37¡ãC. An  Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) antibody(Cat.# S0006), diluted at 1/600, was used as secondary antibod 100 μL 11 to 12 Days
$390.77
Details
Human Rabbit Un-conjugated WB Western blot analysis in NCI-H460 cell line lysates (35ug/lane). 400 μL 2 to 3 Days
$515.63
Details
Human Rabbit Un-conjugated ELISA, IHC, WB   100 μL Available
$363.46
Details
Human Rabbit Un-conjugated WB Western blot analysis of extracts of various cell lines, using CYP4V2 Antibody. 200 μL 12 to 14 Days
$438.90
Details
Human Rabbit Un-conjugated WB CYP4V2 antibody used at 1 ug/ml to detect target protein. 50 μg 9 to 11 Days
$449.29
Details
Human Rabbit Un-conjugated WB Western Blot analysis of CYP4V2 expression in transfected 293T cell line by CYP4V2 MaxPab polyclonal antibody.Lane 1: CYP4V2 transfected lysate(60.70 KDa).Lane 2: Non-transfected lysate. CYP4V2 MaxPab rabbit polyclonal antibody. Western Blot analysis of CYP4V2 expression in human kidney. 100 μg 11 to 12 Days
$425.71
Details
Human Mouse Un-conjugated WB CYP4V2 MaxPab polyclonal antibody. Western Blot analysis of CYP4V2 expression in human liver. Western Blot analysis of CYP4V2 expression in transfected 293T cell line by CYP4V2 MaxPab polyclonal antibody.Lane1:CYP4V2 transfected lysate(57.75 KDa).Lane2:Non-transfected lysate. 50 μg 11 to 12 Days
$440.00
Details
Human Rabbit Un-conjugated ELISA, WB   200 μL 11 to 16 Days
$658.43
Details

More Antibodies against Cytochrome P450, Family 4, Subfamily V, Polypeptide 2 Interaction Partners

Human Cytochrome P450, Family 4, Subfamily V, Polypeptide 2 (CYP4V2) interaction partners

  1. In conclusion, the results of this pooled systematic study indicated that individuals with the A allele had a higher risk of developing venous thromboembolism than those with the C allele of the rs13146272 variant, but the risk was inconsistent among different ethnicities.

  2. The patients with mutations in CYP4V2 showed wide intra- and interfamilial variability in clinical severity. The findings expand the mutational spectrum of CYP4V2 and further confirm the c.802-8_810del17insGC mutation was due to a founder effect in a large cohort of Chinese patients.

  3. To the best of our knowledge, this study represents the largest effort to determine the genetic alterations underlying Bietti crystalline dystrophy (BCD) in Spain to date. Our results show that analysis of CYP4V2 variants is required for a reliable diagnosis of BCD.

  4. This is the first report of a homozygous R400C mutation in CYP4V2 with protein modelling showing high likelihood of enzyme dysfunction. The comprehensive long-term clinical follow-up provides insight into disease progression and highlights possible anti-inflammatory modulation of disease severity.

  5. Bietti crystalline dystrophy patients with CYP4V2 mutations showed more severe macular choroid atrophy as compared to EYS-related RP patients. These different damage patterns suggest differences in choroidal expression between CYP4V2 and EYS.

  6. In summary, we confirmed that the choroideremia-like fundus appearance of our patient was caused by the novel homozygous CYP4V2 variant.

  7. Photoreceptor outer segment and apical retinal pigment epithelium abnormalities underlie the relatively extensive retinal dysfunction observed in relatively early-stage Bietti crystalline dystrophy. Intravitreal Bevacizumab was effective in treating CNV in this setting.

  8. Expression levels of both CYP4V2 mRNA and protein were significantly reduced after treatment with peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist GW9662

  9. Nineteen missense, 4 nonsense, 2 deletion, 2 splice site, and 1 insertion-deletion mutations were identified in in patients with Bietti crystalline corneoretinal dystrophy. The age of the c.802-8_810del17insGC mutation was estimated to be 1040-8200 generations in the Chinese and 300-1100 generations in the Japanese populations.

  10. We found that the subfoveal choroidal thickness and the outer choroidal vascular area were smaller in Bietti Crystalline Dystrophy patients with CYP4V2 mutations than in age-, sex-, AL-, and logMAR VA-matched RP patients with EYS mutations or age-, sex-, and AL-matched healthy controls.

  11. Our findings broaden the spectrum of CYP4V2 mutations that cause BCD and the phenotypic spectrum of the disease in Chinese families. These results will be useful for the genetic diagnosis of BCD, genetic consultation, and gene therapy in the future.

  12. The results of this study demonstrate that causative variants identified in the CTNNA1 and CYP4V2 genes are also associated with Leber Congenital Amaurosis.

  13. Genetic analysis of the CYP4V2 gene revealed a c.802-8_810delinsGC homozygote mutation.

  14. In Bietti crystalline dystrophy patients with CYP4V2 mutations, cone density remained for visual dysfunction by evaluation using high-resolution AO-SLO.

  15. Four novel mutations were identified, contributing to the spectrum of CYP4V2 mutations associated with Bietti's crystalline dystrophy.

  16. cytochrome P450 family 4 subfamily V polypeptide 2 (CYP4V2) c.219T>A (p.F73L) mutation may be a recurrent mutation in Chinese patients with Bietti crystalline dystrophy (BCD).

  17. Likely disease-causing variants were identified in 34 chromosomes from 17 families. Seven were novel, including p.Met66Arg, found in all 11 patients from 8 families of South Asian descent.

  18. This finding suggests that the crystals in the lens of patients with Bietti crystalline corneoretinopathy may be produced in the same way as corneal or retinal crystalline deposits and therefore result from a systemic abnormality of lipid metabolism.

  19. The authors identified a case of Bietti crystalline dystrophy with central and paracentral keratopathy and the molecular analysis of the causative gene in a Spanish family.

  20. The entire coding region and adjacent intronic regions of the CYP4V2 gene were sequenced. Five mutations were identified in the 29-year-old male with Bietti's crystalline dystrophy.

Cytochrome P450, Family 4, Subfamily V, Polypeptide 2 (CYP4V2) Antigen Profile

Protein Summary

This gene encodes a member of the cytochrome P450 hemethiolate protein superfamily which are involved in oxidizing various substrates in the metabolic pathway. It is implicated in the metabolism of fatty acid precursors into n-3 polyunsaturated fatty acids. Mutations in this gene result in Bietti crystalline corneoretinal dystrophy.

Gene names and symbols associated with CYP4V2

  • cytochrome P450 family 4 subfamily V member 2 (CYP4V2) antibody
  • cytochrome P450 family 4 subfamily V member 2 S homeolog (cyp4v2.S) antibody
  • cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2) antibody
  • cytochrome P450 family 4 subfamily V member 2 (cyp4v2) antibody
  • cytochrome P450, family 4, subfamily v, polypeptide 2 (CYP4V2) antibody
  • bcd antibody
  • cyp4ah1 antibody
  • CYP4V antibody
  • MGC147146 antibody

Protein level used designations for CYP4V2

cytochrome P450 4V2 , cytochrome P450, family 4, subfamily V, polypeptide 2

GENE ID SPECIES
285440 Homo sapiens
415121 Gallus gallus
444482 Xenopus laevis
510156 Bos taurus
696520 Macaca mulatta
780124 Xenopus (Silurana) tropicalis
100113469 Sus scrofa
100172140 Pongo abelii
Selected quality suppliers for anti-Cytochrome P450, Family 4, Subfamily V, Polypeptide 2 (CYP4V2) Antibodies
Did you look for something else?